These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35171900)

  • 1. Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.
    Salama H; Fahed Alzayed M; Alharbi KG; Khattak Z; Omer MH; Tahir L; ALhejazi A
    Am J Case Rep; 2022 Feb; 23():e935090. PubMed ID: 35171900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
    Yuen CA; Bao S; Aung MS; Shishodia R; Kong XT
    Per Med; 2024; 21(2):71-78. PubMed ID: 38275171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoalphalipoproteinemia and BRAF
    Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
    Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
    Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multisystem Erdheim-Chester disease presenting with pericardial effusion confirmed by the effusion cytology specimen.
    Dai S; Su X; Liu WP; Wu Y
    Cardiovasc Pathol; 2024; 70():107625. PubMed ID: 38417471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
    Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
    Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erdheim-Chester disease involving the breast--a rare but important differential diagnosis.
    Guo S; Yan Q; Rohr J; Wang Y; Fan L; Wang Z
    Hum Pathol; 2015 Jan; 46(1):159-64. PubMed ID: 25454479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effective treatment in Erdheim Chester disease: vemurafenib: a case report.
    Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
    J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erdheim-Chester disease.
    Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
    Curr Rheumatol Rep; 2014 Apr; 16(4):412. PubMed ID: 24532298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Understanding and Management of Erdheim-Chester Disease.
    Kulkarni AM; Gayam PKR; Aranjani JM
    Life Sci; 2024 Jul; 348():122692. PubMed ID: 38710283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
    Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
    Front Immunol; 2022; 13():918613. PubMed ID: 35874752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.
    Qiao J; Ma R; Peng X; He W
    World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.
    Kanakis M; Petrou P; Lourida G; Georgalas I
    Surv Ophthalmol; 2022; 67(2):388-410. PubMed ID: 34081930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.
    Cangi MG; Biavasco R; Cavalli G; Grassini G; Dal-Cin E; Campochiaro C; Guglielmi B; Berti A; Lampasona V; von Deimling A; Sabbadini MG; Ferrarini M; Doglioni C; Dagna L
    Ann Rheum Dis; 2015 Aug; 74(8):1596-602. PubMed ID: 24671772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
    Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
    Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.